Patents by Inventor Marie-Helene Larraufie

Marie-Helene Larraufie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic AKR1C3 dependent KARS inhibitors
    Patent number: 11970497
    Abstract: The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: April 30, 2024
    Assignee: Novartis AG
    Inventors: Chris Adair, Tracy Chen, Jian Ding, Christy Fryer, Yuko Isome, Marie-Helene Larraufie, Katsumasa Nakajima, Nik Savage, Ariel Sterling Twomey
  • TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS
    Publication number: 20220315582
    Abstract: The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.
    Type: Application
    Filed: July 31, 2020
    Publication date: October 6, 2022
    Inventors: Chris ADAIR, Tracy CHEN, Jian DING, Christy FRYER, Yuko ISOME, Marie-Helene LARRAUFIE, Katsumasa NAKAJIMA, Nik SAVAGE, Ariel Sterling TWOMEY
  • BMP POTENTIATORS
    Publication number: 20190194227
    Abstract: The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: Also provided are methods of making the compounds of Formula (I) and their methods of use.
    Type: Application
    Filed: February 26, 2019
    Publication date: June 27, 2019
    Inventors: Jian DING, Marie-Helene LARRAUFIE, Deborah ROTHMAN, Nik SAVAGE, Shaowen WANG
  • BMP potentiators
    Patent number: 10259827
    Abstract: The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: Also provided are methods of making the compounds of Formula (I) and their methods of use.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: April 16, 2019
    Assignee: NOVARTIS AG
    Inventors: Jian Ding, Marie-Helene Larraufie, Deborah Rothman, Nik Savage, Shaowen Wang
  • BMP POTENTIATORS
    Publication number: 20180127436
    Abstract: The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: Also provided are methods of making the compounds of Formula (I) and their methods of use.
    Type: Application
    Filed: November 8, 2017
    Publication date: May 10, 2018
    Inventors: Jian DING, Marie-Helene LARRAUFIE, Deborah ROTHMAN, Nik SAVAGE, Shaowen WANG
  • Carbonyl erastin analogs and their use
    Patent number: 9938245
    Abstract: The present invention provides, inter alia, compounds having the structure of formula (I): Compositions containing such compounds are also provided. Methods for using such compounds or compositions for treating or ameliorating the effects of a cancer having a cell that harbors an oncogenic RAS mutation, for modulating a lipoxygenase in a ferroptosis cell death pathway, and for depleting reduced glutathione (GSH) in a cell harboring an oncogenic RAS mutation are further provided.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: April 10, 2018
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Brent R. Stockwell, Wan Seok Yang, Marie-Helene Larraufie
  • CARBONYL ERASTIN ANALOGS AND THEIR USE
    Publication number: 20160332974
    Abstract: The present invention provides, inter alia, compounds having the structure of formula (I): Compositions containing such compounds are also provided. Methods for using such compounds or compositions for treating or ameliorating the effects of a cancer having a cell that harbors an oncogenic RAS mutation, for modulating a lipoxygenase in a ferroptosis cell death pathway, and for depleting reduced glutathione (GSH) in a cell harboring an oncogenic RAS mutation are further provided.
    Type: Application
    Filed: January 14, 2015
    Publication date: November 17, 2016
    Inventors: Brent R. Stockwell, Wan Seok Yang, Marie-Helene Larraufie